Life Sciences

Resiliency for times of uncertainty and beyond.

Architects of better-connected health ecosystems for the Transformative Age.

Market turbulence brought on by COVID-19 has contributed to disruptions across all facets of life sciences organizations, including the pressure to rapidly perform, transform and respond all at the same time. Staying competitive while meeting patient demands requires life sciences organizations to find new ways of working. Forming alliances with others to share data, medicine and resources while anticipating trends and regulatory changes will help bring sustainability in the increasingly evidence-based, outcomes-focused sector.

We help companies across the biotechnology, pharmaceutical and medical technology fields harness this disruption by better allocating resources and building trust with customers, especially during times of volatility. Our people understand how to navigate market progressions that challenge the capital strategy of every link in the life sciences value chain, from R&D and supply chain to product launch, salesforce management and patient-centric operating models – where we can help achieve sustainable success.

EY - Business man participating in a videocall

US Health and Life Sciences Executive Summaries

Summaries of cross-industry discussions with insights and resources for responding to volatility and building organizational resilience.

Learn more

Understanding the implications of US health policy during a volatile 2020

Washington Council EY insiders with on-the-ground knowledge deliver Health and Life Sciences sector-specific insights. 



Life Sciences 4.0

When the human body is the biggest data platform, who will capture value?

Learn more 

Direct to your inbox

Stay up to date with our Editor's picks newsletter. 


Contact us

Like what you've seen? Get in touch to learn more.